Moving Product Closer to the Patient
How MEA Disruption Is Accelerating Pharma Network Redesign
Improving speed to patient, resilience, and product availability through smarter supply chain positioning
Pharmaceutical supply chains are undergoing a fundamental shift. Traditionally optimized for global efficiency and cost, these networks are now being redesigned to prioritize resilience, speed, and patient access. Ongoing disruptions across the Middle East and Africa (MEA)—from transport delays to infrastructure constraints—are accelerating this transformation, forcing companies to rethink where they store and distribute critical medical products.
What Does “Moving Closer to the Patient” Mean in Pharma Logistics?
Moving product closer to the patient refers to the strategic placement of inventory in regional or local distribution centers rather than relying solely on centralized global hubs. This approach enables faster response times and reduces dependency on long, complex transport routes.
By decentralizing inventory, pharmaceutical companies can better respond to demand variability, reduce lead times, and improve supply reliability—particularly in regions prone to disruption.
Why Is MEA Disruption Accelerating Network Redesign?
Disruptions across MEA—including port congestion, air freight constraints, and geopolitical instability—have exposed vulnerabilities in traditional supply chain models. Long transit routes can no longer guarantee reliable delivery timelines.
As a result, companies are moving toward regionalization strategies, placing inventory closer to end markets to reduce risk. This shift helps mitigate delays and ensures continuity of supply even when global transport networks are under pressure.
How Does Proximity Improve Patient Outcomes?
For critical therapies and medical devices, time is a decisive factor. Products such as insulin, oncology and cardiology treatment require consistent availability, while pacemakers and other life-saving devices must reach patients without delay.
By reducing the distance between storage and point of use, companies can ensure faster delivery, reduce the risk of stockouts, and improve overall responsiveness to urgent demand. This directly contributes to better patient care and treatment continuity.
How Does Multimodal Logistics Support Regionalization?
Multimodal logistics plays a key role in supporting decentralized networks. By combining air, ocean, and road transport, companies can create flexible and adaptive supply chains that respond to changing conditions.
For example, ocean freight may be used to replenish regional hubs from strategic locations within the Middle East, while air freight or charter solutions ensure rapid distribution to local markets when needed. This integration enhances resilience while balancing cost and speed.
What Are the Challenges of Redesigning Pharma Networks?
Redesigning supply chains requires significant investment in infrastructure, regulatory compliance, and operational coordination. Each country across the MEA region has its own regulatory framework, including customs procedures and Ministry of Health requirements.
Ensuring compliance while managing multiple distribution points adds complexity. However, the benefits of improved resilience and patient access often outweigh these challenges.
How Does DHL Enable Regionalized Pharma Supply Chains?
DHL Global Forwarding supports pharmaceutical companies in redesigning their supply chains to bring products closer to patients. With a strong presence across the MEA region, DHL provides access to strategically located facilities, multimodal transport solutions, and deep regulatory expertise.
Our teams work around the clock to navigate varying regulatory frameworks, ensuring compliance with customs and Ministry of Health requirements across different countries. At the same time, we help optimize distribution strategies, enabling shorter routes and faster delivery times.
By integrating air, ocean, and charter solutions, DHL enables flexible and resilient supply chains that can adapt quickly to disruption while safeguarding product integrity using specialized packaging (e.g. thermal packaging and thermal blankets) and accelerating access to treatment.
Get Logistics Insights by Email
Subscribe to our monthly market updates and get invited to exclusive webinars where our Freight Forwarding Experts answer all your questions on global trade.
What Are the Cost and Strategic Implications of Regionalization?
Regionalizing supply chains may increase inventory holding costs and require additional infrastructure investment. However, these costs must be balanced against the risks of disruption, product loss, and delayed patient care.
In many cases, improved service levels, reduced emergency shipments, and greater resilience can deliver long-term value and operational efficiency.
10 Top Tips for Moving Pharma Products Closer to the Patient
- Assess demand patterns across regional markets.
- Identify strategic locations for regional distribution centers.
- Use multimodal transport to balance cost and speed.
- Ensure compliance with local regulatory frameworks.
- Maintain visibility across all inventory locations.
- Plan for disruption with flexible routing strategies.
- Monitor product stability and shelf-life constraints.
- Collaborate closely with logistics partners.
- Invest in temperature-controlled storage and transport.
- Continuously review and optimize network design.
Explore More Insights on the Life Science and Healthcare Sector
Global logistics solutions for the life sciences and healthcare sector, designed to ensure compliant, temperature‑controlled delivery, supply chain resilience, and patient safety worldwide.
Do You Have a Specific Shipping Challenge You Would like Help With?
Our Shipping Experts are ready to help